RxDoctor Payments Data

Raja Kolisetti, MD

Family Medicine · Batavia, NYNPI 1861460214

Payments from drug & device makers

$2,038in general payments, 2019–2025

Across 29 payments — averaging $70.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$656
  • Avanir Pharmaceuticals, Inc.$467
  • Novo Nordisk$249
  • Johnson & Johnson$229
  • GSK$119
  • Teva Pharmaceuticals USA, Inc.$108
  • plus $211 from 5 others

What the payments were for

  • Food & beverage$1,95396%
  • Education$854%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,038 in reported general payments places this provider in the 75th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$43,027
Medicare patients
73
Services billed
441

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban834$236,205
IngrezzaValbenazine Tosylate16$83,754
Humira PenAdalimumab11$80,456
Glatiramer Acetate20$47,260
MyrbetriqMirabegron169$38,846
FarxigaDapagliflozin Propanediol98$28,848
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$22,804
XareltoRivaroxaban66$19,344
JardianceEmpagliflozin61$16,989
Dalfampridine ErDalfampridine12$13,509
OzempicSemaglutide13$13,349
Pantoprazole Sodium362$10,654
Memantine Hcl177$9,257
Midodrine Hcl87$7,245
Atorvastatin Calcium349$6,585

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$656$31,492109 claims
GSKTrelegy Ellipta$119$22,80444 claims
Johnson & JohnsonXarelto$229$19,34466 claims
Novo NordiskOzempic$249$13,34913 claims
NovartisEntresto$23$3,63117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,321 family medicine providers in New York.

Other family medicine in Batavia

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →